Revolution Medicines (RVMD) Non-Current Assets (2019 - 2026)

Revolution Medicines' Non-Current Assets history runs 8 years deep, the most recent figure standing at $285.8 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 23.86% year-over-year to $285.8 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 218.33% increase from a year earlier, with the FY2025 full-year figure at $279.5 million, up 21.16% from the prior year.
• Non-Current Assets grew to $285.8 million in Q1 2026 per RVMD's latest filing, from $279.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $285.8 million in Q1 2026 and bottomed at -$1.6 billion in Q2 2024.
• The 5-year median for Non-Current Assets is $179.2 million (2024), against an average of $93.7 million.
• Across the five-year window, Non-Current Assets slumped 1134.73% in 2024 and soared 116.13% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $151.7 million in 2022, then increased by 20.22% to $182.4 million in 2023, then gained by 26.45% to $230.7 million in 2024, then climbed by 21.16% to $279.5 million in 2025, then rose by 2.27% to $285.8 million in 2026.
• Per Business Quant, the three latest RVMD Non-Current Assets figures stand at $285.8 million (Q1 2026), $279.5 million (Q4 2025), and $274.4 million (Q3 2025).